They excluded $35M from guidance because they literally can't build it fast enough.
Thesis: Teradyne is an oligopoly Test business disguised as a confused Robotics conglomerate. The Test unit is printing money: 58.8% margins, >80% utilization in Auto, and gaining share in HBM (5% -> 15% of mix). The street focuses on the VIP revenue drop ($100M to $50M) without seeing the diversification. Buy the Test monopoly; the Robotics failure is already priced in and management is finally admitting it.
Verdict: LONG — Conviction: MEDIUM
Catalyst: Q4 revenue clearing the $35M supply constrained backlog plus the UR20 shipments.
Key Risk: Robotics effectively requires $360-400M revenue for breakeven; if the UR20 launch fails, this segment becomes a permanent drag on free cash flow.
The Tell: When asked about Robotics profitability, the President admitted they 'capitulated' against the 5-15% target and that China share is being lost to competitors selling at unprofitable prices. They aren't fighting for it.
Friction Level: MODERATE_FRICTION — Street models cyclical memory recovery; Management signals structural HBM shift. The $35M supply constraint is viewed as risk by Street, backlog by Axe.
Report not found
The report data is no longer available. Please return to the archive.